How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

849 results for

Antithyroid Drug

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

81. Thyroid Suppressibility: Follow-up for Two Years after Antithyroid Treatment (PubMed)

Thyroid Suppressibility: Follow-up for Two Years after Antithyroid Treatment In hyperthyroidism suppression and non-suppression of early radioiodine neck uptake by exogenous thyroid hormone after a course of antithyroid drugs does not indicate clearly those patients who will eventually relapse or have a remission. Sixty-four hyperthyroid patients have been followed up for two years after an 18 to 24 months' course of carbimazole. Twenty-eight patients had suppressed at the end

Full Text available with Trip Pro

1971 British medical journal

82. Triiodothyronine and Thyroxine in Hyperthyroidism COMPARISON OF THE ACUTE CHANGES DURING THERAPY WITH ANTITHYROID AGENTS (PubMed)

Triiodothyronine and Thyroxine in Hyperthyroidism COMPARISON OF THE ACUTE CHANGES DURING THERAPY WITH ANTITHYROID AGENTS In 66 untreated patients with hyperthyroidism, serum triiodothyronine (T(3)) and thyroxine (T(4)) concentrations were measured by immunoassay. The mean T(3) level was 478+/-28 ng/100 ml (all values mean+/-SEM) and the T(4) was 20.6+/-0.6 mug/100 ml. The serum T(4)/T(3) ratio by weight was 48+/-2 as opposed to a value of 71+/-3 in euthyroid adults. There was a significant (...) inverse correlation of the T(4)/T(3) ratios with serum T(3) (r=0.77; P<0.01) but not with serum T(4)(r=0.21). These results suggested that relative overproduction of T(3) is consistently present in patients with hyperthyroidism. To examine the acute effects of various antithyroid agents on serum T(3) and T(4) concentrations, iodide, propylthiouracil (PTU), and methylmercaptoimidazole (MMI) were given alone to mine patients, and serial T(3) and T(4) measurements were made. There was an acute decrease

Full Text available with Trip Pro

1974 Journal of Clinical Investigation

83. Drug-Induced Olfactory Dysfunction

. , , ) (e.g. , ) s s (Lamasil) s s V. Causes: Miscellaneous Antiproliferative drugs (e.g. Cisplatin) Antirheumatic Drugs (e.g. ) Antithyroid Medications s Anticonvulsants Azelastine ( ) Zopiclone (for ) VI. References Images: Related links to external sites (from Bing) These images are a random sampling from a Bing search on the term "Drug-Induced Olfactory Dysfunction." Click on the image (or right click) to open the source website in a new browser window. Related Studies (from Trip Database) Related (...) Drug-Induced Olfactory Dysfunction Drug-Induced Olfactory Dysfunction Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Drug-Induced

2018 FP Notebook

84. Antithyroid drug regimen for treating Graves' hyperthyroidism. (PubMed)

Antithyroid drug regimen for treating Graves' hyperthyroidism. Antithyroid drugs are widely used in the therapy of hyperthyroidism. There are wide variations in the dose, regimen or duration of treatment used by health professionals.To assess the effects of dose, regimen and duration of antithyroid drug therapy for Graves' hyperthyroidism.We searched seven databases and reference lists.Randomised and quasi-randomised trials of antithyroid medication for Graves' hyperthyroidism.Two authors (...) higher in the block-replace group. Three studies considered the addition of thyroxine with continued low dose antithyroid therapy after initial therapy with antithyroid drugs. There was significant heterogeneity between the studies and the difference between the two groups was not significant (OR 0.58, 95% CI 0.05 to 6.21). Four studies considered the addition of thyroxine alone after initial therapy with antithyroid drugs. There was no significant difference in the relapse rates between the groups

2010 Cochrane database of systematic reviews (Online)

85. Benefit of short-term iodide supplementation to antithyroid drug treatment of thyrotoxicosis due to Graves' disease. (PubMed)

Benefit of short-term iodide supplementation to antithyroid drug treatment of thyrotoxicosis due to Graves' disease. Combined treatment with anti-thyroid drugs (ATDs) and potassium iodide (KI) has been used only for severe thyrotoxicosis or as a pretreatment before urgent thyroidectomy in patients with Graves' disease. We compared methimazole (MMI) treatment with MMI + KI treatment in terms of rapid normalization of thyroid hormones during the early phase and examined the later induction

2010 Clinical endocrinology Controlled trial quality: uncertain

86. Thyroid-associated ophthalmopathy; quality of life follow-up of patients randomized to treatment with antithyroid drugs or radioiodine. (PubMed)

Thyroid-associated ophthalmopathy; quality of life follow-up of patients randomized to treatment with antithyroid drugs or radioiodine. The objective of this study was to investigate quality of life (QoL) in patients with Graves' disease treated with radioiodine or antithyroid drugs.The design of the study consists of an open, prospective, randomized multicenter trial between radioiodine and medical treatment. A total of 308 patients were included in the study group: 145 patients in the medical

Full Text available with Trip Pro

2010 European journal of endocrinology / European Federation of Endocrine Societies Controlled trial quality: uncertain

87. Anti-thyroid drug use in pregnancy and birth defects: Why some studies find clear associations, and some studies report none. (PubMed)

defects observed in one study were in general milder and tended to be diagnosed and registered only when they resulted in complications and led to surgery after one year of age. None of the negative studies has investigated outcomes after one year of age.Studies finding no associations between early pregnancy exposure to antithyroid drugs and birth defects were either not sufficiently powered or did not study outcomes at optimal ages. (...) Anti-thyroid drug use in pregnancy and birth defects: Why some studies find clear associations, and some studies report none. Rare cases of birth defects after the use of methimazole (MMI) or carbimazole to treat hyperthyroidism in early pregnancy have been reported since 1972, whereas propylthiouracil (PTU) has not been considered teratogenic. Recently, two studies reported birth defects after the use of MMI in early pregnancy to affect 2-4% of exposed children, and one study also found birth

2015 Thyroid

88. Changes in graves' ophthalmopathy after radioiodine and anti-thyroid drug treatment of graves' disease from 2 prospective, randomized, open-label, blinded end point studies. (PubMed)

than hypothyroidism and to describe the relationship GO changes and the final outcome.In 2 prospective, randomized open-label blinded endpoint trials, patients received radioiodine alone; or, patients received radioiodine or antithyroid drug therapy (ATD). The severity and activity of GO were assessed during a 9-12-year follow-up. The study end points in study 1 were euthyroidism, hyperthyroidism, hypothyroidism, and changes in GO. In study 2, the end points were euthyroidism, hyperthyroidism (...) Changes in graves' ophthalmopathy after radioiodine and anti-thyroid drug treatment of graves' disease from 2 prospective, randomized, open-label, blinded end point studies. A significant association between radioiodine therapy (RIT) and the development or the worsening of pre-existing Graves' ophthalmopathy (GO) has been reported. This post-hoc analysis of 2 studies attempted to describe the changes observed in pre-existing or new-onset GO following RIT with the goal of euthyroidism rather

2014 Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association

89. Teratology and Drug Use During Pregnancy (Treatment)

Teratology and Drug Use During Pregnancy (Treatment) Teratology and Drug Use During Pregnancy: Overview, Approach to Patients Needing Medication During Pregnancy, Example Mechanisms of Teratogenesis Edition: No Results No Results Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. https://profreg.medscape.com/px/getpracticeprofile.do?method=getProfessionalProfile&urlCache (...) =aHR0cHM6Ly9lbWVkaWNpbmUubWVkc2NhcGUuY29tL2FydGljbGUvMjYwNzI1LW92ZXJ2aWV3 processing > Teratology and Drug Use During Pregnancy Updated: Jul 18, 2017 Author: Brittney D Bastow, MD; Chief Editor: Christine Isaacs, MD Share Email Print Feedback Close Sections Sections Teratology and Drug Use During Pregnancy Overview Overview Approximately 3-5% of live births are complicated by a birth defect each year totaling around 120,000 babies. [ ] Drug use is an uncommon cause of birth defects, but certain medications can increase the likelihood of developing a birth defect

2014 eMedicine.com

90. Teratology and Drug Use During Pregnancy (Overview)

Teratology and Drug Use During Pregnancy (Overview) Teratology and Drug Use During Pregnancy: Overview, Approach to Patients Needing Medication During Pregnancy, Example Mechanisms of Teratogenesis Edition: No Results No Results Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. https://profreg.medscape.com/px/getpracticeprofile.do?method=getProfessionalProfile&urlCache (...) =aHR0cHM6Ly9lbWVkaWNpbmUubWVkc2NhcGUuY29tL2FydGljbGUvMjYwNzI1LW92ZXJ2aWV3 processing > Teratology and Drug Use During Pregnancy Updated: Jul 18, 2017 Author: Brittney D Bastow, MD; Chief Editor: Christine Isaacs, MD Share Email Print Feedback Close Sections Sections Teratology and Drug Use During Pregnancy Overview Overview Approximately 3-5% of live births are complicated by a birth defect each year totaling around 120,000 babies. [ ] Drug use is an uncommon cause of birth defects, but certain medications can increase the likelihood of developing a birth defect

2014 eMedicine.com

91. Teratology and Drug Use During Pregnancy (Follow-up)

Teratology and Drug Use During Pregnancy (Follow-up) Teratology and Drug Use During Pregnancy: Overview, Approach to Patients Needing Medication During Pregnancy, Example Mechanisms of Teratogenesis Edition: No Results No Results Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. https://profreg.medscape.com/px/getpracticeprofile.do?method=getProfessionalProfile&urlCache (...) =aHR0cHM6Ly9lbWVkaWNpbmUubWVkc2NhcGUuY29tL2FydGljbGUvMjYwNzI1LW92ZXJ2aWV3 processing > Teratology and Drug Use During Pregnancy Updated: Jul 18, 2017 Author: Brittney D Bastow, MD; Chief Editor: Christine Isaacs, MD Share Email Print Feedback Close Sections Sections Teratology and Drug Use During Pregnancy Overview Overview Approximately 3-5% of live births are complicated by a birth defect each year totaling around 120,000 babies. [ ] Drug use is an uncommon cause of birth defects, but certain medications can increase the likelihood of developing a birth defect

2014 eMedicine.com

92. Teratology and Drug Use During Pregnancy (Diagnosis)

Teratology and Drug Use During Pregnancy (Diagnosis) Teratology and Drug Use During Pregnancy: Overview, Approach to Patients Needing Medication During Pregnancy, Example Mechanisms of Teratogenesis Edition: No Results No Results Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. https://profreg.medscape.com/px/getpracticeprofile.do?method=getProfessionalProfile&urlCache (...) =aHR0cHM6Ly9lbWVkaWNpbmUubWVkc2NhcGUuY29tL2FydGljbGUvMjYwNzI1LW92ZXJ2aWV3 processing > Teratology and Drug Use During Pregnancy Updated: Jul 18, 2017 Author: Brittney D Bastow, MD; Chief Editor: Christine Isaacs, MD Share Email Print Feedback Close Sections Sections Teratology and Drug Use During Pregnancy Overview Overview Approximately 3-5% of live births are complicated by a birth defect each year totaling around 120,000 babies. [ ] Drug use is an uncommon cause of birth defects, but certain medications can increase the likelihood of developing a birth defect

2014 eMedicine.com

93. Primary immune thrombocytopenia responding to antithyroid treatment in a patient with Graves’ disease (PubMed)

Immunoglobulins, Intravenous 8KQ660G60G Carbimazole 9PHQ9Y1OLM Prednisolone IM Ann Hematol. 2011 Oct;90(10):1245-6 21302110 Antithyroid Agents therapeutic use Carbimazole therapeutic use Female Glucocorticoids therapeutic use Graves Disease complications diagnosis immunology Humans Immunoglobulins, Intravenous therapeutic use Platelet Count Prednisolone therapeutic use Thrombocytopenia drug therapy etiology Young Adult 2010 04 14 2010 04 29 2010 5 15 6 0 2010 5 15 6 0 2011 3 4 6 0 ppublish 20467745 10.1007 (...) Primary immune thrombocytopenia responding to antithyroid treatment in a patient with Graves’ disease 20467745 2011 03 03 2018 11 13 1432-0584 90 2 2011 Feb Annals of hematology Ann. Hematol. Primary immune thrombocytopenia responding to antithyroid treatment in a patient with Graves' disease. 223-4 10.1007/s00277-010-0983-4 Gill Harinder H Hwang Yu-Yan YY Tse Eric E eng Case Reports Letter 2010 05 14 Germany Ann Hematol 9107334 0939-5555 0 Antithyroid Agents 0 Glucocorticoids 0

Full Text available with Trip Pro

2010 Annals of hematology

94. Drug-Induced Olfactory Dysfunction

. , , ) (e.g. , ) s s (Lamasil) s s V. Causes: Miscellaneous Antiproliferative drugs (e.g. Cisplatin) Antirheumatic Drugs (e.g. ) Antithyroid Medications s Anticonvulsants Azelastine ( ) Zopiclone (for ) VI. References Images: Related links to external sites (from Bing) These images are a random sampling from a Bing search on the term "Drug-Induced Olfactory Dysfunction." Click on the image (or right click) to open the source website in a new browser window. Related Studies (from Trip Database) Related (...) Drug-Induced Olfactory Dysfunction Drug-Induced Olfactory Dysfunction Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Drug-Induced

2015 FP Notebook

95. Elevated thyroid stimulating hormone in a neonate: Drug induced or disease? (PubMed)

Elevated thyroid stimulating hormone in a neonate: Drug induced or disease? Dyshormonogenesis is an uncommon cause of congenital hypothyroidism. The most common abnormality is absent or insufficient thyroid peroxidase enzyme. Maternal intake of antithyroid drug can also lead to elevated thyroid stimulating hormone (TSH) in a neonate, albeit the scenario is temporary. We report one such interesting case where a clinically euthyroid neonate borne to a mother on antithyroid drug presents on 12(th (...) ) day of life with reports of elevated TSH and increased tracer uptake in 99mTc thyroid scan. Disproportionately high TSH in comparison to low maternal antithyroid drug dosage and further elevation of TSH after stopping mother's antithyroid drugs ruled out maternal antithyroid drug-induced congenital hypothyroidism in the baby. Early institution of therapy in these patients can prevent mental retardation and other features of hypothyroidism.

Full Text available with Trip Pro

2011 Indian journal of endocrinology and metabolism

96. The influence of preoperative drug treatment on the extent of hyperplasia of the thymus in primary thyrotoxicosis. (PubMed)

The influence of preoperative drug treatment on the extent of hyperplasia of the thymus in primary thyrotoxicosis. Thymic biopsies taken from women at the beginning of the operation of subtotal thyroidectomy were studied by the point-counting histometric technique. In all patients with primary thyrotoxicosis, the thymus is hyperplastic. After pretreatment with antithyroid drugs, the pattern of thymic involution with age is similar to, but at higher levels, than that in control groups (...) of patients with non-toxic goitre in whom there is no evidence of immunological abnormality. By contrast, after propranolol pretreatment very little age involution is seen. The differences in the appearance of the thymus in female primary thyrotoxixosis patients prepared for operation with different drug treatment regimes are probably related to the pharmacological actions of the drugs and may indicate an interaction between primary immunological and secondary endocrinological factors in the disease

Full Text available with Trip Pro

1975 Clinical and experimental immunology

97. Innate and drug-induced resistance to acute lung damage caused in rats by alpha-naphthyl thiourea (ANTU) and related compounds. (PubMed)

), with other toxic and non-toxic antithyroid drugs or with iodine or iodide--even if the rats were pretreated at an early age before susceptibility to the agent developed. ANTU-tachyphylaxis was dose-dependent. Total thyroidectomy did not affect either lung damage induced by ANTU or the resistance due to tachyphylaxis or to pretreatment with iodide or the antithyroid drugs thiourea, 1-ethyl-1-phenyl thiourea or propyl thiouracil. Neither total nor medullary adrenalectomy affected ANTU toxicity. Marked (...) Innate and drug-induced resistance to acute lung damage caused in rats by alpha-naphthyl thiourea (ANTU) and related compounds. During the 3rd and 4th weeks of life rats were highly resistant to the toxic effects of alpha-naphthyl thiourea (ANTU) and of thiourea and its derivatives but toxicity developed rapidly during the following 2 weeks. Marked resistance to lung damage by toxic thioureas could be induced in older, mature rats by pretreatment with the toxic agent itself (tachyphylaxis

Full Text available with Trip Pro

1976 British journal of experimental pathology

98. Prolonged drug treatment of hyperthyroidism. (PubMed)

Prolonged drug treatment of hyperthyroidism. 70878 1977 10 31 2018 11 13 0065-7778 88 1977 Transactions of the American Clinical and Climatological Association Trans. Am. Clin. Climatol. Assoc. Prolonged drug treatment of hyperthyroidism. 219-26 Burrows B A BA Slingerland D W DW eng Journal Article Research Support, U.S. Gov't, Non-P.H.S. United States Trans Am Clin Climatol Assoc 7507559 0065-7778 0 Antithyroid Agents 721M9407IY Propylthiouracil IM Antithyroid Agents adverse effects (...) therapeutic use Female Follow-Up Studies Humans Hyperthyroidism drug therapy Hypothyroidism etiology Male Propylthiouracil adverse effects therapeutic use Thyroid Function Tests 1977 1 1 1977 1 1 0 1 1977 1 1 0 0 ppublish 70878 PMC2441413 N Engl J Med. 1960 Jun 16;262:1228-9 13808223 Proc R Soc Med. 1961 Oct;54:869-71 13922623 Br Med J. 1964 Apr 18;1(5389):1005-10 14108470 N Engl J Med. 1964 Nov 12;271:1037-42 14195756 Scott Med J. 1964 Dec;9:505-13 14245982 Metabolism. 1972 Sep;21(9):883-94 4115791 J

Full Text available with Trip Pro

1977 Transactions Of The American Clinical And Climatological Association

99. Drugs for Anginal Pain (PubMed)

Drugs for Anginal Pain 14120952 1996 12 01 2018 12 01 0008-4409 90 1964 Feb 15 Canadian Medical Association journal Can Med Assoc J DRUGS FOR ANGINAL PAIN. 491 SEGALL H N HN eng Journal Article Canada Can Med Assoc J 0414110 0008-4409 0 Antithyroid Agents 0 Vasodilator Agents 7C0697DR9I Atropine 8017-89-8 Amyl Nitrite G59M7S0WS3 Nitroglycerin OM Amyl Nitrite Angina Pectoris Antithyroid Agents Atropine Coronary Vessels Humans Nitroglycerin Vasodilator Agents AMYL NITRITE ANGINA PECTORIS ATROPINE

Full Text available with Trip Pro

1964 Canadian Medical Association Journal

100. To-day's Drugs: Treatment of Thyroid Disorders (PubMed)

To-day's Drugs: Treatment of Thyroid Disorders 14161993 1996 12 01 2018 12 01 0007-1447 2 5407 1964 Aug 22 British medical journal Br Med J TO-DAY'S DRUGS. TREATMENT OF THYROID DISORDERS. 493-7 WAYNE E E BLACKBURN G G DAVIS R H RH eng Journal Article England Br Med J 0372673 0007-1447 0 Antithyroid Agents 0 Iodine Isotopes OM Antithyroid Agents Female Goiter Graves Disease Heart Diseases Humans Iodine Isotopes therapeutic use Pregnancy Pregnancy Complications Thyroid Diseases Thyroidectomy

Full Text available with Trip Pro

1964 British medical journal

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>